AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 21 - (NewsRx.com & NewsRx.net) --
by Michelle Marble, staff medical writer -- Researchers in the United States hope that one day a simple vaccine may help treat certain cancers.
"Basic fibroblast growth factor (FGF-2) is an important stimulator of angiogenesis that has been implicated in neoplastic progression," wrote S.M. Plum and colleagues of EntreMed Inc., Rockville, Maryland. "Attempts to neutralize or modulate FGF-2 have met with some success in controlling neovascularity and tumor growth."
"In the present study, two peptides, one corresponding to the heparin binding domain and the other to the receptor binding domain of FGF-2, exerted dose-dependent inhibition of FGF-2-stimulated human umbilical vein endothelial cell proliferation (IC[50]=70 and 20 (micro)g/ml, respectively)," the researchers said. "The identification of these functional regions suggested that targeting these domains might be an approach for the modulation of FGF-2 function."
Both peptides were in a liposome/adjuvant format. Mice were vaccinated with one or the other. The researchers then analyzed the effect of the vaccines on FGF-2-driven angiogenesis, tumor development, and immune status in two tumor models: the B16BL6 melanoma and the Lewis lung carcinoma.
According to the authors, the mice vaccinated with the heparin binding domain peptide generated a specific antibody response to FGF-2. These mice blocked ...
Source: HighBeam Research, Growth-Factor-Based Vaccine Abrogates Angiogenesis and Tumor...